This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Deshpande, L. M. Articles by Jones, R. N. Search for Related Content PubMed PubMed Citation Articles by Deshpande, L. M. Articles by Jones, R. N.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, October 2006, p. 3775-3777, Vol. 44, No. 10
0095-1137/06/$08.00+0     doi:10.1128/JCM.00456-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Contemporary Prevalence of BRO ß-Lactamases in Moraxella catarrhalis: Report from the SENTRY Antimicrobial Surveillance Program (North America, 1997 to 2004)

JMI Laboratories, North Liberty, Iowa,¹ Tufts University School of Medicine, Boston, Massachusetts²

Received 2 March 2006/ Returned for modification 19 April 2006/ Accepted 22 July 2006

A total of 7,860 community-acquired Moraxella catarrhalis isolates (SENTRY Antimicrobial Surveillance Program, 1997 to 2004) were tested by broth microdilution methods, and 399 randomly selected strains from North American sites were tested for BRO-1 and BRO-2 by PCR methods. Several antimicrobials remained very active, including amoxicillin-clavulanate (MIC₉₀s, 0.25 µg/ml), azithromycin (MIC₉₀s, 0.12 µg/ml), ceftriaxone (MIC₉₀s, 0.5 µg/ml), and levofloxacin (MIC₉₀s, 0.03 to 0.06 µg/ml). The BRO-2 incidence rates by year were 3 to 4% overall (96 to 97% for BRO-1) and were the highest in Canada (7.9%), with the incidence in the United States being only 2.0%.